Cargando…
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
BACKGROUND: Myo-inositol (or inositol) and its derivatives not only function as important metabolites for multiple cellular processes but also act as co-factors and second messengers in signaling pathways. Although inositol supplementation has been widely studied in various clinical trials, little i...
Autores principales: | Li, Ji-Min, Chang, Wen-Hsin, Li, Linhui, Yang, David C., Hsu, Ssu-Wei, Kenyon, Nicholas J., Chen, Ching-Hsien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189934/ https://www.ncbi.nlm.nih.gov/pubmed/37194070 http://dx.doi.org/10.1186/s12931-023-02421-6 |
Ejemplares similares
-
ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017) -
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary
fibrosis
por: Lyu, Xing, et al.
Publicado: (2019) -
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
por: Skurikhin, Evgenii, et al.
Publicado: (2020) -
Antifibrotic Mechanism of Piceatannol in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Sheng, Hanjing, et al.
Publicado: (2022) -
Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
por: Miao, Yang, et al.
Publicado: (2023)